Reply to: “Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment” - 21/06/19
Funding sources: Dr Porter received the AAD Resident and Fellow QI grant for this project. Funding from this grant was for the implementation of the pharmacy intervention, specifically office supplies and funding to cover travel for Dr Porter to the 2018 AAD annual meeting to present the QI project at the QI symposium. No funding from the project was used specifically for the research presented in this article. |
|
Conflicts of interest: Dr Flood receives fellowship funding from AbbVie, Janssen, and the National Psoriasis Foundation. Dr Kimball is a consultant and investigator for AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. She receives fellowship funding from AbbVie and Janssen. Dr Porter is a consultant and investigator for AbbVie and Novartis. She is also an investigator for Bristol-Myers Squibb, Eli Lilly, Janssen, and UCB. She has previously received fellowship funding from AbbVie, Janssen and the National Psoriasis Foundation. Mr Savage, Ms Popatia, Ms Gobari, and Ms Salian have no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 81 - N° 1
P. e19-e20 - juillet 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?